Ischemic postconditioning: An effective strategy of myocardial protection?;II postcondizionamento ischemico: Un'efficace strategia di protezione miocardica?

Giornale Italiano di Cardiologia

Volumn 7, Issue 7, 2006, Pages 464-473

  Rastaldo, Rafaella ^a   Penna, Claudia ^a   Cappello, Sandra ^a   Mancardi, Daniele ^a   Pagliaro, Pasquale ^a   Losano, Gianni ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Ischemic preconditioning; Myocardial; Reperfusion

Indexed keywords

ADENOSINE; ANTIOXIDANT; ATORVASTATIN; NITRIC OXIDE; NITRIC OXIDE DONOR; OXIDIZING AGENT; PHOSPHOTRANSFERASE; REACTIVE OXYGEN METABOLITE;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CLINICAL EFFECTIVENESS; CONTROL STRATEGY; DRUG EFFICACY; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART PROTECTION; HUMAN; INFLAMMATION; ISCHEMIC PRECONDITIONING; NONHUMAN; PATHOGENESIS; REPERFUSION INJURY; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CORONARY ARTERY BLOOD FLOW; DRUG POTENTIATION; HEART INFARCTION; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; RAT; REVIEW; TIME;

ADENOSINE; ANIMALS; ANTIOXIDANTS; CORONARY CIRCULATION; DRUG SYNERGISM; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; NITRIC OXIDE; NITRIC OXIDE DONORS; PHOSPHOTRANSFERASES; RATS; TIME FACTORS;

EID: 33750119757     PISSN: 18276806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (100)

1. Follette DM, Fey K, Buckberg GD, et al. Reducing postischemic damage by temporary modification of reperfusate calcium, potassium, pH, and osmolarity. J Thorac Cardiovasc Surg 1981; 82: 221-38.
2. Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword? J Clin Invest 1985; 76: 1713-9.
3. Buckberg GD. When is cardiac muscle damaged irreversibly? J Thorac Cardiovasc Surg 1986; 92: 483-7.
4. Ambrosio G, Tritto I, Chiariello M. The role of oxygen free radicals in preconditioning. J Mol Cell Cardiol 1995; 27: 1035-9.
5. Pagliaro P, Gattullo P, Rastaldo R, Losano G. Ischemic preconditioning: from the first to the second window of protection. Life Sci 2001; 69: 1-15.
6. Jneid H, Leessar M, Both R. Cardiac preconditioning during percutaneous coronary interventions. Cardiovasc Drugs Ther 2005; 19: 211-7.
7. Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003; 285: H579-H588.
8. Kin H, Zhao QZ, Sun YH, et al. Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res 2004: 62: 74-85.
9. Yang XM, Philipp S, Downey JM, Cohen MV. Postconditioning's protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires PI3-kinase and guanylyl cyclase activation. Basic Res Cardiol 2005; 100: 57-63.
10. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM. Post-conditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res 2004; 95: 230-2.
11. Penna C, Cappello S, Mancardi D, et al. Post-conditioning reduces infarct size in the isolated rat heart: role o coronary flow and pressure and the nitric oxide/cGMP pathway. Basic Res Cardiol 2006; 101: 168-79.
12. + channel and protein kinase C activation. Basic Res Cardiol 2006; 101: 180-9.
13. Heusch G. Postconditioning: old wine in a new bottle? J Am Coll Cardiol 2004; 44: 1111-2.
14. Valen G, Vaage J. Pre- and postconditioning during cardiac surgery. Basic Res Cardiol 2005; 100: 179-86.
15. Staat P, Rioufol G, Piot C, et al. Postconditioning the human heart. Circulation 2005; 112: 2143-8.
16. Zhao ZQ, Vinten-Johansen J. Myocardial apoptosis and ischemic preconditioning. Cardiovasc Res 2002; 55: 438-55.
17. Ambrosio G, Zweier JL, Flaherty JT. The relationship between oxygen radical generation and impairment of myocardial energy metabolism following post-ischemic reperfusion. J Mol Cell Cardiol 1991; 23: 1359-74.
18. Ambrosio G, Zweier JL, Duilio C, et al. Evidence that mitochondrial respiration is a source of potentially toxic oxygen free radicals in intact rabbit hearts subjected to ischemia and reflow. J Biol Chem 1993; 268: 18532-41.
19. Hoffman JW Jr, Gilbert TB, Poston RS, Silldorf EP. Myocardial reperfusione injury: etiology, mechanisms and therapies. J Extra Corpor Technol 2004; 36: 391-411.
20. Zhao ZQ. Oxidative stress-elicited myocardial apoptosis during reperfusion. Curr Opin Pharmacol 2004; 4: 159-65.
21. Kaeffer N, Richard V, Thuillez C. Delayed coronary endothelial protection 24 hours after preconditioning: role of free radicals. Circulation 1997; 96: 2311-6.
22. Beauchamp P, Richard V, Tamion F, et al. Protective effects of preconditioning in cultured rat endothelial cells: effects on neutrophil adhesion and expression of ICAM-1 after anoxia and reoxygenation. Circulation 1999; 100: 541-6
23. Lefer DJ, Scalia R, Campbell B, et al. Peroxynitrite inhibits leukocyte-endothelial cell interactions and protects against ischemia-reperfusion injury in rats. J Clin Invest 1997; 99: 684-91.
24. Ronson RS, Nakamura M, Vinten-Johansen J. The cardiovascular effects and implications of peroxynitrite. Cardiovasc Res 1999; 44: 47-59.
25. Ferdinandy P, Schulz R. Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. Br J Pharmacol 2003; 138: 532-43.
26. Schreck R, Albermann K, Baeuerle PA. Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukariotic cells (a review). Free Radic Res Commun 1992; 17: 221-37.
27. Marczin N, El-Habashi N, Hoare GS, Bundy RE, Yacoub M. Antioxidant in myocardial ischemia-reperfusion injury: therapeutic potential and basic mechanisms. Arch Biochem Biophys 2003; 420: 222-36.
28. Lefer AM, Lefer DJ. The role of nitric oxide and cell adhesion molecules on the microcirculation in ischaemia-reperfusion. Cardiovasc Res 1996; 32: 743-51.
29. Baldwin AS Jr. Series introduction: the transcription factor NF-kB and human disease. J Clin Invest 2001; 107: 3-6.
30. Radomski MW, Palmer RM, Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol 1987; 92: 181-7.
31. Schulz R, Kelm M, Heusch G. Nitric oxide in myocardial ischemia/ reperfusion injury. Cardiovasc Res 2004; 61: 402-13.
32. Reffelmann T, Kloner RA. Microvascular alterations after temporary coronary artery occlusion: the no-reflow phenomenon. J Cardiovasc Pharmacol Ther 2004; 9: 163-72.
33. Nithipatikom K, Endsley MP, Moore IM, et al. Effects of selective inhibition of cytochrome P-450 omega-hydroxylases and ischemic preconditioning in myocardial protection. Am J Physiol Heart Circ Physiol 2006; 290: H500-H505.
34. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-36.
35. Reimer KA, Murry CE, Jennings RB. Cardiac adaptation to ischemia. Ischemic preconditioning increases myocardial tolerance to subsequent ischemic episodes. Circulation 1990; 82: 2266-8.
36. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 2003; 83: 1113-51.
37. Schott RJ, Rohman S, Braun ER, Schaper W. Ischemic preconditioning reduces infarct size in swine myocardium. Circ Res 1990; 66: 1133-42.
38. Parratt JR, Vegh A, Papp JG. Bradykinin as an endogenous myocardial protective substance with particular reference to ischemic preconditioning - a brief review of the evidence. Can J Physiol Pharmacol 1995; 73: 837-42.
39. DeFily DV, Chilian WM. Preconditioning protects coronary arteriolar endothelium from ischemic-reperfusion injury. Am J Physiol 1993; 265 (Suppl 2): H700-H706.
40. Gattullo D, Linden RJ, Losano G, Pagliaro P, Westerhof N. Ischemic preconditioning changes the pattern of coronary reactive hyperaemia in the goat: role of adenosine and nitric oxide. Cardiovasc Res 1999; 42: 57-64.
41. Pagliaro P, Rastaldo R, Losano G, Gattullo D. Mitochondrial potassium ATP-sensitive channel opener does not induce vascular preconditioning, but potentiates the effect of a preconditioning ischemia on coronary reactive hyperemia in the anesthetized goat. Pflugers Arch 2001; 443: 166-74.
42. (+) channel blockade. Life Sci 2002; 71: 2299-309.
43. Nakamura M, Wang NP, Zhao ZQ, et al. Preconditioning decreases Bax expression, PMN accumulation and apoptosis in reperfused rat heart. Cardiovasc Res 2000; 45: 661-70.
44. Qiu Y, Tang XL, Park SW, Sun JZ, Kalya A, Bolli R. The early and late phases of ischemic preconditioning: a comparative analysis of their effects on infarct size, myocardial stunning, and arrhythmias in conscious pigs undergoing a 40-minute coronary occlusion. Circ Res 1997; 80: 730-42.
45. Bolli R. The late phase of preconditioning. Circ Res 2000; 87: 972-83.
46. Tsang A, Hausenloy DJ, Yellon DM. Myocardial postconditioning: reperfusion injury revisited. Am J Physiol Heart Circ Physiol 2005; 289: H2-H7.
47. ATP channels, and ERK. Am J Physiol Heart Circ Physiol 2004; 286: H1433-H1440.
48. Gong KZ, Zhang ZG, Li AH, et al. ROS-mediated ERK activation in delayed protection from anoxic preconditioning in neonatal rat cardiomyocytes. Chin Med J 2004; 117: 395-400.
49. Otani H. Reactive oxygen species as mediators of signal transduction in ischemic preconditioning. Antioxid Redox Signal 2004; 6: 449-69.
50. Tritto I, Ambrosio G. Role of oxidants in the signaling pathway of preconditioning. Antioxid Redox Signal 2001; 3: 3-10.
51. Kaeffer N, Richard V, Thuillez C. Delayed coronary endothelial protection 24 hours after preconditioning: role of free radicals. Circulation. 1997; 96: 2311-6.
52. Yamashita N, Hoshida S, Taniguchi N, Kuzuya T, Hori M. A "second window of protection" occurs 24 h after ischemic preconditioning in the rat heart. J Mol Cell Cardiol 1998; 30: 1181-9.
53. Hausenloy DJ, Tsang A, Yellon DM. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med 2005; 15: 69-75.
54. Argaud L, Gateau-Roesch O, Raisky O, Loufouat J, Robert D, Ovize M. Postconditioning inhibits mitochondrial permeability transition. Circulation 2005; 111: 194-7.
55. Penna C, Alloatti G, Cappello S, et al. Platelet-activating factor induces cardioprotection in isolated rat heart akin to ischemic preconditioning: role of phosphoinositide 3-kinase and protein kinase C activation. Am J Physiol Heart Circ Physiol 2005; 288: H2512-H2520.
56. Turan N, Csonka C, Csont T, et al. The role of peroxynitrite in chemical preconditioning with 3-nitropropionic acid in rat hearts. Cardiovasc Res 2006; 70: 384-90.
57. Leesar MA, Stoddard MF, Dawn B, Jasti VG, Masden R, Bolli R. Delayed preconditioning-mimetic action of nitroglycerin in patients undergoing coronary angioplasty. Circulation 2001; 103: 2935-41.
58. (1) receptor mediates late preconditioning via activation of PKC-delta signaling pathway. Am J Physiol Heart Circ Physiol 2002; 283: H296-H301.
59. Kloner RA. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation 2004; 110: 3149-55.
60. Hudman D, Standen NB. Protection from the effects of metabolic inhibition and reperfusion in contracting isolated ventricular myocytes via protein kinase C activation. J Mol Cell Cardiol 2004; 37: 579-91.
61. Fryer RM, Wang Y, Hsu AK, Nagase H, Gross GJ. Dependence of delta1-opioid receptor-induced cardioprotection on a tyrosine kinase-dependent but not a Src-dependent pathway. J Pharmacol Exp Ther 2001; 299: 477-82.
62. Wong TM, Wu S. Role of kappa opioid receptor in cardioprotection of preconditioning: implications in cardiac surgery. J Card Surg 2002; 17: 462-4.
63. Peart JN, Gross GJ. Cardioprotection following adenosine kinase inhibition in rat hearts. Basic Res Cardiol 2005; 100: 328-36.
64. + channels. Possible mechanism of cardioprotection. Circ Res 1997; 81: 1072-82.
65. Sato H, Jordan JE, Zhao ZQ, Sarvotham SS, Vinten-Johansen J. Gradual reperfusion reduces infarct size and endothelial injury but augments neutrophil accumulation. Ann Thorac Surg 1997; 64: 1099-107.
66. Crestanello JA, Lingle DM, Kamelgard J, Millili J, Whitman GJ. ischemic preconditioning decreases oxidative stress during reperfusion: a chemiluminescence study. J Surg Res 1996; 65: 53-8.
67. Sochman J. N-acetylcysteine in acute cardiology: 10 years later: what do we know and what would we like to know?! J Am Coll Cardiol 2002; 39: 1422-8.
68. Davidson SM, Hausenloy D, Duchen MR, Yellon DM. Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. Int J Biochem Cell Biol 2006; 38: 414-9.
69. Jonassen AK, Aasum E, Riemersma RA, Mjos OD, Larsen TS. Glucose-insulin-potassium reduces infarct size when administered during reperfusion. Cardiovasc Drugs Ther 2000; 14: 615-23.
70. Jonassen AK, Sack MN, Mjos OD, Yellon DM. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 2001; 89: 1191-8.
71. Gao F, Gao E, Yue TL, et al. Nitric oxide mediates the anti-apoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation 2002; 105: 1497-502.
72. Beauloye C, Bertrand L, Krause U, et al. No-flow ischemia inhibits insulin signaling in heart by decreasing intracellular pH. Circ Res 2001; 88: 513-9.
73. Otani H, Yamamura T, Nakao Y, et al. Insulin-like growth factor-I improves recovery of cardiac performance during reperfusion in isolated rat heart by a wortmannin-sensitive mechanism. J Cardiovasc Pharmacol 2000; 35: 275-81.
74. Parrizas M, Saltiel AR, LeRoith D. Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways. J Biol Chem 1997; 272: 154-61.
75. Baxter GF, Mocanu MM, Brar BK, Latchman DS, Yellon DM. Cardioprotective effects of transforming growth factor-beta1 during early reoxygenation or reperfusion are mediated by p42/p44 MAPK. J Cardiovasc Pharmacol 2001; 38: 930-9.
76. Liao Z, Brar BK, Cai Q, et al. Cardiotrophin-1 (CT 1) can protect the adult heart from injury when added both prior to ischaemia and at reperfusion. Cardiovasc Res 2002; 53: 902-10.
77. Brar BK, Stephanou A, Liao Z, et al. Cardiotrophin-1 can protect cardiac myocytes from injury when added both prior to simulated ischaemia and at reoxygenation. Cardiovasc Res 2001; 51: 265-74.
78. Bell RM, Yellon DM. Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS. J Mol Cell Cardiol 2003; 35: 185-93.
79. Bell RM, Yellon DM. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 2003; 41: 508-15.
80. Bose AK, Mocanu MM, Carr RD, Yellon DM. Glucagon like peptide-1 is protective against myocardial inschemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther 2005: 19: 9-11.
81. Scarabelli TM, Pasini E, Stephanou A, et al. Urocortin promotes hemodynamic and bioenergetic recovery and improves cell survival in the isolated rat heart exposed to ischemia/reperfusion. J Am Coll Cardiol 2002; 40: 155-61.
82. Halkos ME, Kerendi F, Corvera JS, et al. Myocardial protection with postconditioning is not enhanced by ischemic preconditioning. Ann Thor Surg 2004: 78: 961-9.
83. Yang XM, Proctor JB, Cui L, Krieg T, Downey JM, Cohen MV. Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol 2004; 44: 1103-10.
84. Galagudza M, Kurapeev D, Minasian S, Valen G, Vaage J. Ischemic postconditioning: brief ischemia during reperfusion convert persistent ventricular fibrillation into regular rhythm. Eur J Cardiothor Syrg 2004; 25: 1006-10.
85. Zweier JL, Flaherty JT, Weisfeld ML. Direct measurement of free radicals generated following reperfusion of ischemic myocardium. Proc Nat Acad Sci 1987; 84: 1404-7.
86. 2 radicals during reperfusion after prolonged myocardial ischemia. Am J Physiol Heart Circ Physiol 2001; 280: H2649-H2657.
87. 2+ overload. Am J Physiol Heart Circ Physiol 2005; 288: H1900-H1908.
88. Tremblay J, Desjardins R, Hum D, Gutkowska J, Hamet P. Biochemistry and physiology of the natriuretic peptide receptor guanylyl cyclases. Mol Cell Biochem 2002; 230: 31-47.
89. Piper HM, Abdallah Y, Schäfer C. The first minute of reperfusion: a window of opportunity for cardioprotection. Cardiovasc Res 2004; 61: 365-71.
90. Bernardi P, Petronilli V. The permeability transitions pore as a mitochondrial calcium release channel: a critical appraisal. J Bioenerg Biomembr 1996; 28: 129-36.
91. Halestrap AP, Doran E, Gillespie JP, O'Toole A. Mitochondria and cell death. Biochem Soc Trans 2000; 28: 170-7.
92. + and in a causative event in the death of myocytes in postischemic reperfusion of the heart. J Biol Chem 2001; 276: 2571-5.
93. Zweier JL, Samouilov A, Kuppusamy P. Non-enzymatic nitric oxide synthesis in biological systems. Biochim Biophys Acta 1999; 1411: 250-62.
94. Tiravanti E, Samouilov A, Zweier JL. Nitrosyl-heme complexes are formed in the ischemic heart: evidence of nitrite-derived nitric oxide formation, storage, and signalling in post-ischemic tissues. J Biol Chem 2004; 279: 11065-73.
95. Hempel A, Friedric M, Schlüter KD, Forssmann WG, Kuhn M, Piper HM. ANP protects against reoxygenation-induced hypercontractura in adult cardiomyocytes. Am J Physiol 1997; 273: H244-H249.
96. Padilla F, Garcia-Dorado D, Agullo L, et al. Intravenous administration of the natriuretic peptide urodilatin at low doses uring coronary reperfusion limits infarct size in anesthetized pigs. Cardiovasc Res 2001; 5: 592-600.
97. Zatta AJ, Kin H, Lee G, et al. Infarct-sparing effect of myocardial postconditioning is dependent on protein kinase C signalling. Cardiovasc Res 2006; 70: 315-24.
98. Yellon DM, Opie LH. Postconditioning for protection of the infarcting heart. Lancet 2006; 367: 456-8.
99. Becker LB. New concepts in reactive oxygen species and cardiovascular reperfusion physiology. Cardiovasc Res 2004; 6: 461-70.
100. Kin H, Zatta AJ, Lofye MT, et al. Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Cardiovasc Res 2005; 67: 124-33.